Smith & Nephew (NYSE: SNN) and Uroplasty (NASDAQ:UPI) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Risk and Volatility

Smith & Nephew has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Uroplasty has a beta of -1.26, indicating that its stock price is 226% less volatile than the S&P 500.

Institutional & Insider Ownership

6.4% of Smith & Nephew shares are held by institutional investors. 1.0% of Smith & Nephew shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.


This table compares Smith & Nephew and Uroplasty’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Smith & Nephew N/A N/A N/A
Uroplasty -31.58% -87.33% -60.82%


Smith & Nephew pays an annual dividend of $0.61 per share and has a dividend yield of 1.8%. Uroplasty does not pay a dividend. Uroplasty has increased its dividend for 4 consecutive years.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Smith & Nephew and Uroplasty, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew 0 3 1 0 2.25
Uroplasty 0 0 0 0 N/A

Smith & Nephew presently has a consensus target price of $42.00, indicating a potential upside of 20.93%. Given Smith & Nephew’s higher possible upside, analysts plainly believe Smith & Nephew is more favorable than Uroplasty.

Valuation and Earnings

This table compares Smith & Nephew and Uroplasty’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Smith & Nephew $4.67 billion 3.25 $784.00 million N/A N/A
Uroplasty N/A N/A N/A ($0.30) -4.07

Smith & Nephew has higher revenue and earnings than Uroplasty.


Smith & Nephew beats Uroplasty on 10 of the 11 factors compared between the two stocks.

Smith & Nephew Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.

Uroplasty Company Profile

Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with's FREE daily email newsletter.